Showing results (241-250 of 351) with videos related to
Sort By:
Pageof 36
Journal of Gastroenterology|November 19, 2004
Efficacy of 6-month interferon therapy in chronic hepatitis B virus infection in JapanFumitaka Suzuki, Yasuji Arase, Norio Akuta, et al.Hepatology International|April 15, 2016
Impact of circulating miR-122 for histological features and hepatocellular carcinoma of nonalcoholic fatty liver disease in JapanNorio Akuta, Yusuke Kawamura, Fumitaka Suzuki, et al.Journal of Medical Virology|September 15, 2017
Serial changes in liver stiffness and controlled attenuation parameter following direct-acting antiviral therapy against hepatitis C virus genotype 1bNobuhiko Ogasawara, Masahiro Kobayashi, Norio Akuta, et al.Journal of Gastroenterology|August 24, 2018
Long-term outcome of entecavir treatment of nucleos(t)ide analogue-naïve chronic hepatitis B patients in JapanFumitaka Suzuki, Tetsuya Hosaka, Yoshiyuki Suzuki, et al.Journal of Medical Virology|February 19, 2010
Clinical and virological effects of long-term (over 5 years) lamivudine therapyYoshimasa Hashimoto, Fumitaka Suzuki, Miharu Hirakawa, et al.Journal of Medical Virology|August 21, 2007
Loss of hepatitis B surface antigen from the serum of patients with chronic hepatitis treated with lamivudineMariko Kobayashi, Fumitaka Suzuki, Norio Akuta, et al.Clinics and Research in Hepatology and Gastroenterology|September 9, 2021
Clinicopathological assessment of steatohepatitic hepatocellular carcinomaKenji Yamaoka, Satoshi Saitoh, Keiichi Kinowaki, et al.Journal of Gastroenterology|February 10, 2004
Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudineMarie Matsuda, Fumitaka Suzuki, Yoshiyuki Suzuki, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|October 1, 2009
Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatmentMariko Kobayashi, Fumitaka Suzuki, Norio Akuta, et al.Oncology|April 28, 2017
Outcome of All-Oral Direct-Acting Antiviral Regimens on the Rate of Development of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Genotype 1-Related Chronic Liver DiseaseFumihiro Ogata, Masahiro Kobayashi, Norio Akuta, et al.Pageof 36